Phathom Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Willow AK United States (2019)

Organization Overview

First Clinical Trial
2019
NCT04124926
First Marketed Drug
2022
clarithromycin (biaxin)
First NDA Approval
2022
vonoprazan (Voquezna)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

PHATHOM | Phathom Pharmaceuticals | Phathom Pharmaceuticals, Inc.

Active Ingredients

Marketed Drugs (3)

amoxicillin (2022)

clarithromycin (biaxin) (2022)

vonoprazan (Voquezna) (2022 NDA)

Drugs in Phase 3 Trials (4)

amoxicillin (1 trial)

clarithromycin (biaxin) (1 trial)

lansoprazole (prevacid) (3 trials)

vonoprazan (Voquezna) (6 trials)

Drugs in Phase 1 Trials (2)

midazolam (versed) (1 trial)

rifampin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Esophagitis (Phase 3)

Helicobacter Infections (Phase 3)

Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 6